Gout: Current insights and future perspectives

Journal of Pain

Volumn 12, Issue 11, 2011, Pages 1113-1129

  Smith, Howard S ^a   Bracken, Donna ^b   Smith, Joshua M ^c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

allopurinol; febuxostat; Gout; IL 1 inhibitors; pain; pegloticase; treatment

Indexed keywords

ALLOPURINOL; BREAST CANCER RESISTANCE PROTEIN; CELECOXIB; CLARITHROMYCIN; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOSPORIN; DICLOFENAC; ETODOLAC; ETORICOXIB; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MELOXICAM; METHYLPREDNISOLONE; NAPROXEN; PLACEBO; PREDNISOLONE; PREDNISONE; PROBENECID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; ROFECOXIB; SULINDAC; TRIAMCINOLONE; UNINDEXED DRUG; URATE;

ABDOMINAL PAIN; BIREFRINGENCE; CHRONIC DISEASE; CINCA SYNDROME; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DIZZINESS; DRUG MEGADOSE; DYSPNEA; ECHOGRAPHY; GENE MUTATION; GOUT; HEART PALPITATION; HUMAN; HYPERURICEMIA; JOINT ASPIRATION; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHYSICAL EXAMINATION; PRURITUS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE;

EID: 80255131323     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2011.06.009     Document Type: Review

References (118)

1. C.A. Agudelo, A. Weinberger, H.R. Schumacher, R. Turner, and J. Molina Definitive diagnosis of gout by identification for urate crystals in asymptomatic metatarsophalangeal joints Arthritis Rheum 22 1979 559 560 (Pubitemid 10146157)
2. R.D. Altman, S. Honig, J.M. Levin, and R.W. Lightfoot Ketoprofen versus indomethacin in patients with acute gouty arthritis: A multicenter, double blind comparative study J Rheumatol 15 1988 1422 1426
3. Anderson A, Singh JA: Pegloticase for chronic gout. Cochrane Database Syst Rev (3): CD008335, 2010
4. H.S. Baraf, A.K. Matsumoto, A.N. Maroli, and R.W. Waltrip 2nd Resolution of gouty tophi after twelve weeks of pegloticase treatment Arthritis Rheum 58 2008 3632 3634
5. M.A. Becker, and S. Chohan We can make gout management more successful now Curr Opin Rheumatol 20 2008 167 172 (Pubitemid 351339888)
6. M.A. Becker, M.J. Losman, P. Itkin, and P.A. Simkin Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate J Lab Clin Med 99 1982 495 511 (Pubitemid 12086372)
7. M.A. Becker, H.R. Schumacher, K.L. Benjamin, P. Gorevic, M. Greenwald, J. Fessel, L. Edwards, A.K. Kawata, L. Frank, R. Waltrip, A. Maroli, and B. Huang Gout Natural History Study Group J.S. Sundy Quality of life and disability in patients with treatment-failure gout J Rheumatol 36 2009 1041 1048
8. M.A. Becker, H.R. Schumacher Jr., R.L. Wortmann, P.A. MacDonald, D. Eustace, W.A. Palo, J. Streit, and N. Joseph-Ridge Febuxostat compared with allopurinol in patients with hyperuricemia and gout N Engl J Med 353 2005 2450 2461 (Pubitemid 41781828)
9. G.C. Borstad, L.R. Bryant, M.P. Abel, D.A. Scroggie, M.D. Harris, and J.A. Alloway Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis J Rheumatol 31 2004 2429 2432 (Pubitemid 39610535)
10. D.I. Brixner, and M.J. Ho Clinical, humanistic, and economic outcomes of gout Am J Manag Care 11 Suppl 15 2005 S459 S464
11. C.M. Burns, and R.L. Wortmann Gout therapeutics: New drugs for an old disease Lancet 377 2011 165 177
12. G.N. Cattermole, C.Y. Man, C.H. Cheng, C.A. Graham, and T.H. Rainer Oral prednisolone is more cost-effective than oral indomethacin for treating patients with acute gout-like arthritis Eur J Emerg Med 16 2009 261 266
13. J. Chao, and R. Terkeltaub A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout Curr Rheumatol Rep 11 2009 135 140
14. T.T. Cheng, H.M. Lai, C.K. Chiu, and Y.C. Chem A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis Clin Ther 26 2004 399 406
15. H.K. Choi, A. Al-Arfaj, S. Nicolaou, P.L. Munk, K. Shojania, G. Reid, and S. Nicolaou Dual energy computed tomography in tophaceous gout Ann Rheum Dis 68 2008 1609 1612
16. H.K. Choi, K. Atkinson, E.W. Karlson, W. Willett, and G. Curhan Purine-rich foods, dairy and protein intake, and the risk of gout in men N Engl J Med 350 2004 1093 1103 (Pubitemid 38298989)
17. H.K. Choi, K. Atkinson, E.W. Karlson, W. Willett, and G. Curhan Alcohol intake and risk of incident gout in men: A prospective study Lancet 363 2004 1277 1281 (Pubitemid 38496489)
18. H.K. Choi, and G. Curhan Soft drinks, fructose consumption, and the risk of gout in men: Prospective cohort study BMJ 336 2008 309 312 (Pubitemid 351278368)
19. H.K. Choi, X. Gao, and G. Curhan Vitamin C intake and the risk of gout in men: A prospective study Arch Intern Med 169 2009 502 507
20. H.K. Choi, D.B. Mount, and A.M. Reginato Pathogenesis of gout Ann Intern Med 143 2005 499 516 (Pubitemid 41379398)
21. N.L. Edwards, B. Gout, and J.H. Klippel Clinical and Laboratory Features, in Primer on the Rheumatic Diseases 2007 Springer New York, NY, London, UK
22. M. Connor Allopurinol for pain relief: More than just crystal clearance? Br J Pharmacol 156 2009 4 6
23. J.C. Crawhall, J.F. Henderson, and W.N. Kelley Diagnosis and treatment of the Lesch-Nyhan syndrome Pediatr Res 6 1972 504 513
24. K. Dahan, A. Fuchshuber, S. Adamis, M. Smaers, S. Kroiss, G. Loute, J.P. Cosyns, F. Hildebrandt, C. Verellen-Dumoulin, and Y. Pirson Familial juvenile hyperuricemic nephropathy and autosomal dominant medullary cystic kidney disease type 2: Two facets of the same disease? J Am Soc Nephrol 12 2001 2348 2357 (Pubitemid 33021112)
25. R.O. Day, G.G. Graham, M. Hicks, A.J. McLachlan, S.L. Stocker, and K.M. Williams Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol Clin Pharmacokinet 46 2007 623 644 (Pubitemid 47204850)
26. E. De Ávila Fernandes, E.S. Kubota, G.B. Sandim, S.A. Miltraud, A.J. Ferrari, and A.R. Fernandes Ultrasound features of tophi in chronic tophaceous gout Skeletal Radiol 40 2011 309 315
27. A. Dehghan, A. Köttgen, Q. Yang, S.J. Hwang, W.L. Kao, F. Rivadeneira, E. Boerwinkle, D. Levy, A. Hofman, B.C. Astor, E.J. Benjamin, C.M. van Duijn, J.C. Witteman, J. Coresh, and C.S. Fox Association of three genetic loci with uric acid concentration and risk of gout: A genome-wide association study Lancet 372 2008 1953 1961
28. N.L. Edwards, J.S. Sundy, A. Forsythe, S. Blume, F. Pan, and M.A. Becker Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy J Med Econ 14 2011 10 15
29. M.E. Ernst, and M.A. Fravel Febuxostat: A selective xanthine-oxidase/ xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout Clin Ther 31 2009 2503 2518
30. Febuxostat (Uloric) for chronic treatment of gout Med Lett Drugs Ther 51 2009 37
31. C. Fernández, R. Noguera, J.A. González, and E. Pascual Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide J Rheumatol 26 1999 2285 2286 (Pubitemid 29487039)
32. E. Filippucci, C.A. Scir, A. Delle Sedie, A. Iagnocco, L. Riente, G. Meenagh, M. Gutierrez, S. Bombardieri, G. Valesini, C. Montecucco, and W. Grassi Ultrasound imaging for the rheumatologist. XXV. Sonographic assessment of the knee in patients with gout and calcium pyrophosphate deposition disease Clin Exp Rheumatol 28 2010 2 5
33. Y. Finkelstein, S.E. Aks, J.R. Hutson, D.N. Juurlink, P. Nguyen, G. Dubnov-Raz, U. Pollak, G. Koren, and Y. Bentur Colchicine poisoning: The dark side of an ancient drug Clin Toxicol (Phila) 48 2010 407 414
34. Fitz-Patrick D, Drummond W, Pappas J, Hollister AS: Effects of a Purine Nucleoside Phosphorylase Inhibitor, BCX4208, on the Serum Uric Acid Concentrations in Patients with Gout. American College of Rheumatology Annual Meeting, Atlanta, Georgia; Abstract 150, November 2010
35. S.R. Gnanenthiran, G.M. Hassett, K.A. Gibson, and H.P. McNeil Acute gout management during hospitalisation: A need for a protocol Intern Med J 2010 Jan 4 [Epub ahead of print]
36. R. Goldbach-Mansky Blocking interleukin-1 in rheumatic diseases. Its initial disappointments and recent successes in the treatment of autoinflammatory diseases Ann N Y Acad Sci 1182 2009 111 123
37. A. Graser, T.R. Johnson, M. Bader, M. Staehler, N. Haseke, K. Nikolaou, M.F. Reiser, C.G. Stief, and C.R. Becker Dual energy CT characterization of urinary calculi: Initial in vitro and clinical experience Invest Radiol 43 2008 112 119
38. W. Grassi, G. Meenagh, E. Pascual, and E. Filippucci "Crystal clear" - sonographic assessment of gout and calcium pyrophosphate deposition disease Semin Arthritis Rheum 36 2006 197 202 (Pubitemid 44691886)
39. L.R. Harrold, S.E. Andrade, B. Briesacher, M.A. Raebel, H. Fouayzi, R.A. Yood, and I.S. Ockene The dynamics of chronic gout treatment: Medication gaps and return to therapy Am J Med 123 2010 54 59
40. H.M. Hoffman, and S.D. Brydges The genetic and molecular basis of inflammasome-mediated disease J Biol Chem 2011 Feb 4 [Epub ahead of print]
41. D.J. Hunter, M. York, C.E. Chaisson, R. Woods, J. Niu, and Y. Zhang Recent diuretic use and the risk of recurrent gout attacks: The online case-crossover gout study J Rheumatol 33 2006 1341 1345 (Pubitemid 44026423)
42. T.L. Jansen, P. Richette, F. Perez-Ruiz, A.K. Tausche, P.A. Guerne, L. Punzi, B. Leeb, V. Barskova, T. Uhlig, J. Pimentão, I. Zimmermann-Górska, E. Pascual, T. Bardin, and M. Doherty International position paper on febuxostat Clin Rheumatol 2010 Apr 18 [Epub ahead of print]
43. H.J. Janssens, J. Fransen, E.H. van de Lisdonk, P.L. van Riel, C. van Weel, and M. Janssen A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis Arch Intern Med 170 2010 1120 1126
44. H.J. Janssens, M. Janssen, E.H. van de Lisdonk, J. Fransen, P.L. van Riel, and C. van Weel Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care Ann Rheum Dis 69 2010 1255 1256
45. H.J. Janssens, M. Janssen, E.H. van de Lisdonk, P.L. van Riel, and C. van Weel Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial Lancet 371 2008 1854 1860 (Pubitemid 351736009)
46. Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH: Systemic corticosteroids for acute gout. Cochrane Database Syst Rev (2): CD005521, 2008
47. M.F. Jarvis, H. Yu, S. McGaraughty, C.T. Wismer, J. Mikusa, C. Zhu, K. Chu, K. Kohlhaas, M. Cowart, C.H. Lee, A.O. Stewart, B.F. Cox, J. Polakowski, and E.A. Kowaluk Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor Pain 96 2002 107 118 (Pubitemid 34270633)
48. E. Kawenoki-Minc, and Z. Zieliński Effect of balneotherapy in Ciechocinek Spa on the occurrence of gouty attacks and the symptoms of chronic gouty arthropathy (observations of 112 cures) Pol Med J11 1972 1494 1500
49. P.P. Khanna, F. Perez-Ruiz, P. Maranian, and D. Khanna Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: Short form-36 is responsive to change in chronic gout Rheumatology (Oxford) 50 2011 740 745
50. D. Khanna, A.J. Sarkin, P.P. Khanna, M.M. Shieh, A.F. Kavanaugh, R.A. Terkeltaub, S.J. Lee, J.A. Singh, and J.D. Hirsch Minimally important differences of the gout impact scale in a randomized controlled trial Rheumatology (Oxford) 2011 Mar 3 [Epub ahead of print]
51. R. Khosravan, B.A. Grabowski, J.T. Wu, N. Joseph-Ridge, and L. Vernillet Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects Clin Pharmacokinet 45 2006 821 841 (Pubitemid 44192308)
52. K.H. Ko, Y.C. Hsu, H.S. Lee, C.H. Lee, and G.S. Huang Tophaceous gout of the knee: Revisiting MRI patterns in 30 patients J Clin Rheumatol 16 2010 209 214
53. R.C. Lawrence, D.T. Felson, C.G. Helmick, L.M. Arnold, H. Choi, R.A. Deyo, S. Gabriel, R. Hirsch, M.C. Hochberg, G.G. Hunder, J.M. Jordan, J.N. Katz, H.M. Kremers, F. Wolfe National Arthritis Data Workgroup Estimates of the prevalence of arthritis and other rheumatic conditions in the United States Part II. Arthritis Rheum 58 2008 26 35
54. S.E. Liebman, J.G. Taylor, and D.A. Bushinsky Uric acid nephrolithiasis Curr Rheumatol Rep 9 2007 251 257 (Pubitemid 46954785)
55. C.X. Lin, H.F. Ma, W.Z. Ma, and P.J. Zhou Clinical application of acupuncture and moxibustion to the treatment of gouty arthritis and analysis on their therapeutic effects Zhen Ci Yan Jiu 34 2009 67 69
56. B. Liu, H.M. Wang, and F.Y. Wang Observation on therapeutic effect of electroacupuncture combined with local blocking therapy on acute gouty arthritis Zhongguo Zhen Jiu 28 2008 659 661
57. A. Maccagno, E. Di Giorgio, and A. Romanowicz Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout Curr Med Res Opin 12 1991 423 429
58. C.Y. Man, I.T. Cheung, P.A. Cameron, and T.H. Rainer Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: A double-blind, randomized, controlled trial Ann Emerg Med 49 2007 670 677 (Pubitemid 46601694)
59. B.F. Mandell, N.L. Edwards, J.S. Sundy, P.A. Simkin, and J.C. Pile Preventing and treating acute gout attacks across the clinical spectrum: A roundtable discussion Cleve Clin J Med 77 Suppl 2 2010 S2 S25
60. F. Martinon Signaling by ROS drives inflammasome activation Eur J Immunol 40 2010 616 619
61. The Medical Letter on Drugs and Therapeutics. February 7, 53:9-12, 2011
62. J.U. Monu, and T.L. Pope Jr. Gout: A clinical and radiologic review Radiol Clin North Am 42 2004 169 184 (Pubitemid 38292196)
63. S. Nalbant, L.X. Chen, M.S. Sieck, G. Clayburne, and H.R. Schumacher Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch J Rheumatol 32 2005 1762 1764 (Pubitemid 41324819)
64. T. Neogi Clinical practice. Gout N Engl J Med 364 2011 443 452
65. T.C. Ning, and R.T. Keenan Unusual clinical presentations of gout Curr Opin Rheumatol 22 2010 181 187
66. Y. Niu, H. Zhu, J. Liu, H. Fan, L. Sun, W. Lu, X. Liu, and L. Li 3,5,2′,4′-Tetrahydroxychalcone, a new non-purine xanthine oxidase inhibitor Chem Biol Interact 189 2011 161 166
67. G. Nuki, and P. Simkin A concise history of gout and hyperuricemia and their treatment Arthritis Res Ther 8 2006 S1
68. A. Ogdie, S. Hoch, J. Dunham, and J.M. Von Feldt A roadmap for education to improve the quality of care in gout Curr Opin Rheumatol 22 2010 173 180
69. E. Pascual, E. Batlle-Gualda, A. Martinez, J. Rosas, and P. Vela Synovial fluid analysis for diagnosis of intercritical gout Ann Intern Med 131 1999 756 759 (Pubitemid 29531985)
70. I. Peláez-Ballestas, C. Hernández Cuevas, R. Burgos-Vargas, L. Hernández Roque, L. Terán, J. Espinoza, J.A. Esquivel-Valerio, M.V. Goycochea-Robles, F.J. Aceves, A.G. Bernard, L. Ventura, C. Shumsky, A. Hernández Garduño, and J. Vázquez-Mellado Diagnosis of chronic gout: Evaluating the american college of rheumatology proposal, European league against rheumatism recommendations, and clinical judgment J Rheumatol 37 2010 1743 1748
71. W. Rezende-Lima, K.S. Parreira, M. García-González, E. Riveira, J.F. Banet, and X.M. Lens Homozygosity for uromodulin disorders: FJHN and MCKD-type 2 Kidney Int 66 2004 558 563 (Pubitemid 38981995)
72. P. Richette, and T. Bardin Gout Lancet 375 2010 318 328
73. K.T. Rott, and C.A. Agudelo Gout JAMA 289 2003 2857 2860 (Pubitemid 37441258)
74. B.R. Rubin, R. Burton, S. Navarra, J. Antigua, J. Londoño, K.G. Pryhuber, M. Lund, E. Chen, D.K. Najarian, R.A. Petruschke, Z.E. Ozturk, and G.P. Geba Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial Arthritis Rheum 50 2004 598 606 (Pubitemid 38202232)
75. J.N. Scalapino, W.D. Edwards, J.M. Steckelberg, R.S. Wooten, J.A. Callahan, and W.W. Ginsburg Mitral stenosis associated with valvular tophi Mayo Clin Proc 59 1984 509 512 (Pubitemid 14087061)
76. N. Schlesinger, D.G. Baker, and H.R. Schumacher Jr. Serum urate during bouts of acute gouty arthritis J Rheumatol 24 1997 2256 2265
77. N. Schlesinger, M.A. Detry, B.K. Holland, D.G. Baker, A.M. Beutler, M. Rull, B.I. Hoffman, and H.R. Schumacher Jr. Local ice therapy during bouts of acute gouty arthritis J Rheumatol 29 2002 331 334 (Pubitemid 34118783)
78. N. Schlesinger Diagnosis of gout: Clinical, laboratory, and radiologic findings Am J Manag Care 11 Suppl 15 2005 S443 S450
79. N. Schlesinger, U. Yaspthan, and P. Kirkpatrick Pegloticase Nat Rev Drug Discov 10 2011 17 18
80. A.P. Schmidt, A.E. Bohmer, C. Antunes, C. Schallenberger, L.O. Poriuncula, E. Elisabetsky, D.R. Lara, and D.O. Souza Antinociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: Role of adenosine A1 receptors Br J Pharmacol 156 2009 163 172
81. Schorn C, Frey B, Janko C, Schett G, Herrmann M: The NALP3 Inflammasome Is Activated by Sodium Overload and Water Influx in Gouty Arthritis. American College of Rheumatology Annual Meeting; Atlanta, Georgia; Abstract 2150, November 2010
82. H.R. Schumacher Jr., M.S. Sieck, S. Rothfuss, G.M. Clayburne, D.F. Baumgarten, B.S. Mochan, and J.A. Kant Reproducibility of synovial fluid analyses: A study among four laboratories Arthritis Rheum 29 1986 770 774 (Pubitemid 16094154)
83. H.R. Schumacher, J.A. Boice, D.I. Daikh, S. Mukhopadhyay, K. Malmstrom, J. Ng, G.A. Tate, and J. Molina Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis BMJ 324 2002 1488 1492 (Pubitemid 34666615)
84. H.R. Schumacher Jr., M.A. Becker, R.L. Wortmann, P.A. MacDonald, B. Hunt, J. Streit, C. Lademacher, and N. Joseph-Ridge Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial Arthritis Rheum 59 2008 1540 1548
85. Schumacher HR, Berger M, Li-Yu J, Perez-Ruiz F, Burgos Vargas R, Li C: Efficacy and Tolerability of Celecoxib in the Treatment of Moderate to Extreme Pain Associated with Acute Gouty Arthritis: A Randomized Controlled Trial. American College of Rheumatology Annual Meeting; Atlanta, Georgia; Abstract 151, November 2010
86. J.E. Seegmiller, R.M. Dixon, G.J. Kemp, P.W. Angus, T.E. McAlindon, P. Dieppe, B. Rajagopalan, and G.K. Radda Fructose-induced aberration of metabolism in familial gout identified by 31P magnetic resonance spectroscopy Proc Natl Acad Sci U S A 87 1990 8326 8330
87. M. Shrestha, D.L. Morgan, J.M. Moreden, R. Singh, M. Nelson, and J.E. Hayes Randomized doubleblind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis Ann Emerg Med 26 1995 682 686
88. D. Singh, and K.K. Huston IL-1 inhibition with anakinra in a patient with refractory gout J Clin Rheumatol 15 2009 366
89. J. Singh Quality of life and quality of care for patients with gout Curr Rheumatol Rep 11 2009 154 160
90. J. Singh, J. Hodges, and S. Asch Opportunities for improving medication use and monitoring in gout Ann Rheum Dis 68 2009 1265 1270
91. A. So, T. De Smedt, S. Revaz, and J. Tschopp A pilot study of IL-1 inhibition by anakinra in acute gout Arthritis Res Ther 9 2007 R28
92. A. So, M. De Meulemeester, A. Pikhlak, A.E. Yücel, D. Richard, V. Murphy, U. Arulmani, P. Sallstig, and N. Schlesinger Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study Arthritis Rheum 62 2010 3064 3076
93. So A, De Meulemeester M, Pikhlak A, Yücel1 AE, Arulmani U, Richard D, Stricker K, Ferreira A, Murphy V, Sallstig P, Schlesinger N: Rapid Improvement in Health-Related Quality of Life (HRQoL) in Gouty Arthritis Patients Treated with Canakinumab (ACZ885) Compared to Triamcinolone Acetonide. American College of Rheumatology Annual Meeting; Atlanta, Georgia; Abstract 1423, November 2010
94. C. Stehlik, and A. Dorfleutner COPs and POPs: Modulators of inflammasome activity J Immunol 179 2007 7993 7998
95. S.L. Stocker, K.M. Williams, A.J. McLachlan, G.G. Graham, and R.O. Day Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects Clin Pharmacokinet 47 2008 111 118
96. S.L. Stocker, G.G. Graham, A.J. McLachlan, K.M. Williams, and R.O. Day Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout J Rheumatol 2011 Feb 1 [Epub ahead of print]
97. J.S. Sundy, N.J. Ganson, S.J. Kelly, E.L. Scarlett, C.D. Rehrig, W. Huang, and M.S. Hershfield Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout Arthritis Rheum 56 2007 1021 1028 (Pubitemid 46399452)
98. J.S. Sundy Gout management: Let's get it right this time Arthritis Rheum 59 2008 1535 1537
99. J.S. Sundy, H.S. Baraf, M.A. Becker, S.R. Edwards, S.R. Gutierrez-Urena, E.L. Treadwell, J. Vázquez-Mellado, R.A. Yood, Z. Horowitz, W. Huang, A.N. Maroli, and R.W. Waltrip Efficacy and safety of intravenous (IV) pegloticase (PGL) in subjects with treatment failure gout (TFG): Phase 3 results from GOUT1 and GOUT2 [Abstract] Arthritis Rheum 58 Suppl 2008 S400
100. J.S. Sundy, M.A. Becker, H.S. Baraf, A. Barkhuizen, L.W. Moreland, W. Huang, R.W. Waltrip 2nd, A.N. Maroli, and Z. Horowitz Pegloticase Phase 2 Study Investigators: Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study Arthritis Rheum 58 2008 2882 2891
101. S. Sutaria, R. Katbamna, and M. Underwood Effectiveness of interventions for the treatment of acute and prevention of recurrent gout - a systematic review Rheumatology (Oxford) 45 2006 1422 1431 (Pubitemid 44605481)
102. S. Tassi, S. Carta, L. Delfino, R. Caorsi, A. Martini, M. Gattorno, and A. Rubartelli Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion Proc Natl Acad Sci U S A 107 2010 9789 9794
103. R. Terkeltaub Learning how and when to employ uricase as bridge therapy in refractory gout J Rheumatol 34 2007 1955 1958 (Pubitemid 47548194)
104. R.A. Terkeltaub Colchicine Update Semin Arthritis Rheum 38 2008 411 419
105. R. Terkeltaub, J.S. Sundy, H.R. Schumacher, F. Murphy, S. Bookbinder, S. Biedermann, R. Wu, S. Mellis, and A. Radin The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study Ann Rheum Dis 68 2009 1613 1617
106. R. Terkeltaub Update on gout: New therapeutic strategies and options Nat Rev Rheumatol 6 2010 30 38
107. R.A. Terkeltaub, D.E. Furst, K. Bennett, K.A. Kook, R.S. Crockett, and M.W. Davis High vs low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study Arthritis Rheum 62 2010 1060 1068
108. J. Tschopp, and K. Schroder NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production Nat Rev Immunol 10 2010 210 215
109. US Food and Drug Administration. FDA labeling information - Krystexxa (pegloticase). FDA website [online]. Available at: http://www.accessdata.fda. gov/drugsatfda-docs/label/2010/125293s0000lbl.pdf. Accessed August 11, 2011
110. US FDA. Rheumatology information: Non-selective nonsteroidal anti-inflammatory drugs [online]. Available at: http://www.fda.gov/Drugs/ ResourcesForYou/HealthProfessionals/ucm106979.htm. Accessed July 2, 2010
111. G. Welch, K. Weinger, and M.J. Barry Quality-of-life impact of lower urinary tract symptom severity: Results from the Health Professionals Follow-up Study Urology 59 2002 245 250 (Pubitemid 34134525)
112. R.L. Wortmann, P.A. Macdonald, B. Hunt, and R.L. Jackson Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials Clin Ther 32 2010 2386 2397
113. Yang X, Dick R, Borges V, Yazdani N, Green A, Manhard K, Quart B, Yeh L: Evaluation of Drug-Drug Interaction Potential between RDEA594, Alloputinal and Febuxostat in Preclinical Species. ACR-ARHP Annual Scientific Meeting; Philadelphia, PA; Poster #1102, October 2009
114. L.P. Yang Oral colchicine (Colcrys): In the treatment and prophylaxis of gout Drugs 70 2010 1603 1613
115. Yeh L, Hingorani V, Manhard K, Borges V, Nguyen M, Tieu K, Quart B: Safety and uric acid lowering effect in humans following multiple doses of RDEA806, a novel prodrug for the potential treatment of hyperuricemia. Annual European Congress of Rheumatology EULAR; Paris, France; Poster #THU0356, June 2008
116. Yeh L, Kerr B, Shen Z, Hingorani V, Sheedy B, Nguyen M, Polvent L, Manhard K, Quart B: Safety, pharmacokinetics, and serum uric acid lowering effect of RDEA594, a novel uricosuric agent, in healthy volunteers. Annual European Congress of Rheumatology EULAR; Copenhagen, Denmark; Poster THU0451, June 2009
117. W. Zhang, M. Doherty, T. Bardin, E. Pascual, V. Barskova, P. Conaghan, J. Gerster, J. Jacobs, B. Leeb, F. Lioté, G. McCarthy, P. Netter, G. Nuki, F. Perez-Ruiz, A. Pignone, J. Pimentão, L. Punzi, E. Roddy, T. Uhlig, I. Zimmermann-Grska EULAR Standing Committee for International Clinical Studies Including Therapeutics EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 65 2006 1312 1324 (Pubitemid 44620440)
118. Y. Zhang, R. Woods, C.E. Chaisson, T. Neogi, J. Niu, T.E. McAlindon, and D. Hunter Alcohol consumption as a trigger of recurrent gout attacks Am J Med 119 2006 800.e13 800.e18